

Contents

Contents		
A Word of Gratitude		i
Acknowledgements		ii
Registration Details		v
Abbreviations		vi
List of Tables		x
List of Figures		xiii
Preface		
1. Introduction to Hyperlipidemia		1
1.1. Introduction		1
1.2. Atherosclerosis		3
1.2.1. Development of an Atherosclerotic Plaque		4
1.3. Lipoproteins		7
1.3.1. Composition of Lipoproteins		7
1.3.2. Comparison of Cholesterol <i>versus</i> Cholesterol Ester		8
1.3.3. Functions of Lipoproteins		8
1.3.4. Classification of Lipoproteins		8
1.3.5. Lipoprotein Synthesis		10
1.3.6. Lipoprotein Metabolism		11
1.3.7. The Link between Lipoproteins and Cardiovascular diseases		12
1.4. Classification of Hyperlipidemias		13
1.4.1. Types of Hyperlipoproteinemias		14
1.5. Treatments of Hyperlipidemia		15
1.5.1. Non pharmacological Treatments		15
1.5.2. Pharmacological Treatments		15
1.5.2.1. HMG-CoA Reductase Inhibitors		16
1.5.2.2. Fibrates		17
1.5.2.3. Nicotinic Acid		19
1.5.2.4. Bile Acid Sequestrants (Anion-exchange Resins)		19
1.5.2.5. Cholesterol Absorption Inhibitors		21
1.6. Antihyperlipidemic Ezetimibe and Azetidin-2-ones		21
1.6.1. Mechanism of Action at NPC1L1 Protein		22
1.6.2. Azetidin-2-ones		23
1.7. References		25

Contents

2.	The Chemistry and Biological Potential of Azetidin-2-ones: Review	29
2.1.	Introduction	29
2.2.	Chemistry of Azetidin-2-ones	29
2.3.	Reactivity of Azetidin-2-ones	30
2.4.	Methods of Synthesis of Azetidin-2-ones	30
2.5.	Biological and Medicinal Significance of Azetidin-2-ones	32
2.5.1.	Antimicrobial Activity	33
2.5.2.	Antitubercular Activity	44
2.5.3.	Anticancer Activity	46
2.5.4.	Human Cytomegalovirus Protease Activity	49
2.5.5.	Cholesterol Absorption Inhibitory Activity	51
2.5.6.	Antidiabetic Activity	56
2.5.7.	Tryptase and Chymase Inhibitory Activity	57
2.5.8.	Human Leukocyte Elastase Inhibitory Activity	58
2.5.9.	Analgesic and Anti-inflammatory Activities	60
2.5.10.	Thrombin Inhibitory Activity	61
2.5.11.	Antiparkinsonian Activity	61
2.5.12.	Cysteine Protease CathepsinK Inhibitor Activity	61
2.5.13.	Vasopressin VIa Antagonist Activity	62
2.5.14.	Anticonvulsant Activity	63
2.6.	References	64
3.	Design, Synthesis and Antihyperlipidemic Evaluation of Condensed 2-(1-(Substitutedphenyl)-4-oxoazetidin-2-yl)pyrimidin-4(3H)-ones	67
3.1.	Introduction	67
3.2.	Problems in Current Therapy of Hyperlipidemia	67
3.3.	Thieno[2,3- <i>d</i>]pyrimidin-4(3 <i>H</i>)-ones as Antihyperlipidemic Agents	68
3.4.	Cholesterol Absorption Inhibitors	69
3.5.	Aim of the Present Work	70
3.6.	Docking Studies	71
3.7.	Synthetic Plan	84
3.8.	Results & Discussion: Plan of Work	85
3.9.	Chemical Synthesis	86
3.9.1.	Synthesis of <i>o</i> -Aminoester Substrates (II–iv)	86

Contents

3.9.2.	Synthesis of Condensed 2-Chloromethylpyrimidin-4(3 <i>H</i>)-ones (III- <i>iv</i>)	87
3.9.3.	Synthesis of Condensed 2-(Substitutedphenyl)aminomethylpyrimidin-4(3 <i>H</i>)-ones (III- <i>xx</i>)	88
3.9.4.	Synthesis of 2-Chloro- <i>N</i> -[4-oxo-condensedpyrimidin-2-ylmethyl]- <i>N</i> -substitutedphenylacetamides (IV- <i>xx</i>)	89
3.9.5.	Synthesis of Condensed 2-(1-(Substitutedphenyl)-4-oxoazetidin-2-yl)-pyrimidin-4(3 <i>H</i>)-ones (V- <i>xx</i>)	90
3.10.	Physical Properties and Spectral Discussion	92
3.10.1.	Physical Properties and Spectral Characteristics of <i>o</i> -Aminoester Substrates (I- <i>iv</i>)	92
3.10.2.	Physical Properties and Spectral Characteristics of Condensed 2-Chloromethylpyrimidin-4-ones (I- <i>iv</i>)	96
3.10.3.	Physical Properties and Spectral Characteristics of Condensed 2-(Substitutedphenyl)aminomethylpyrimidin-4(3 <i>H</i>)-ones (III- <i>xx</i>)	102
3.10.4.	Physical Properties and Spectral Characteristics of 2-Chloro- <i>N</i> -[4-oxo-condensedpyrimidin-2-ylmethyl]- <i>N</i> -substitutedphenylacetamides (IV- <i>xx</i>)	107
3.10.5.	Physical Properties and Spectral Characteristics of Condensed 2-(1-(Substitutedphenyl)-4-oxoazetidin-2-yl)-pyrimidin-4(3 <i>H</i>)-ones (V- <i>xx</i>)	115
3.11.	Biological Evaluation	119
3.12.	Experimental: Chemical Synthesis	125
3.12.1.	Synthesis of Starting Material (Chloroacetonitrile)	125
3.12.2.	Synthesis of <i>o</i> -Aminoester Substrates (I- <i>iv</i>)	126
3.12.3.	Synthesis of Condensed 2-Chloromethylpyrimidin-4(3 <i>H</i>)-ones (III- <i>iv</i>)	128
3.12.4.	Synthesis of Condensed 2-(Substitutedphenyl)aminomethylpyrimidin-4(3 <i>H</i>)-ones (III- <i>xx</i>)	130
3.12.5.	Synthesis of 2-Chloro- <i>N</i> -[4-oxo-condensedpyrimidin-2-ylmethyl]- <i>N</i> -substitutedphenylacetamides (IV- <i>xx</i>)	138
3.12.6.	Synthesis of Condensed 2-(1-(Substitutedphenyl)-4-oxo-	147

Contents

	azetidin-2-yl)pyrimidin-4(3 <i>H</i>)-ones (Vi-xx)	
3.13.	Biological Screening	158
3.14.	References	163
4.	Design, Synthesis and Biological Evaluation of some 2-Azetidinone Derivatives as Potential Antihyperlipidemic Agents	167
	(Series-a: <i>N</i>-[4-(Substitutedphenyl)-2-oxo-3-substituted-azetidin-1-yl]arylamides)	167
4.1.	Introduction	167
4.2.	Aim of the Present Work	168
4.3.	Docking Studies	169
4.4.	Synthetic Plan	175
4.5.	Results & Discussion: Plan of Work	176
4.6.	Chemical Synthesis	177
4.6.1.	Synthesis of Aryl/ heteroaryl hydrazides (VIi-iv)	177
4.6.2.	Synthesis of <i>N'</i> -(Substitutedbenzylidene)aryl/heteroaryl-hydrazides (Schiff's Bases) (VIIi-xii)	178
4.6.3.	Synthesis of <i>N</i> -[4-(Substitutedphenyl)-2-oxo-3-substituted-azetidin-1-yl]-arylamides (VIIIi-xvi)	179
4.7.	Physical Properties and Spectral Discussion	182
4.7.1.	Physical Properties and Spectral Characteristics of Aryl/heteroaryl hydrazides (VIi-iv)	182
4.7.2.	Physical Properties and Spectral Characteristics of <i>N'</i> -(substitutedbenzylidene)aryl/heteroarylhydrazides (Schiff's Bases) (VIIi-xii)	186
4.7.3.	Physical Properties and Spectral Characteristics of <i>N</i> -[4-(Substitutedphenyl)-2-oxo-3-substituted-azetidin-1-yl]-arylamides (VIIIi-xvi)	194
4.8.	Biological Evaluation	198
4.9.	Experimental: Chemical Synthesis	203
4.9.1.	Synthesis of Aryl/heteroaryl hydrazides (VIi-iv)	203
4.9.2.	Synthesis of <i>N'</i> -(Substitutedbenzylidene)aryl/heteroaryl-hydrazides (Schiff's Bases) (VIIi-xii)	205
4.9.3.	Synthesis of <i>N</i> -[4-(Substitutedphenyl)-2-oxo-3-substituted-	210

Contents

	azetidin-1-yl]-arylamides (VIIIi–xvi)	
4.10.	Biological Screening	218
	(Series-b: 3-Substituted-4-aryl-1-phenylaminoazetidin-2-ones)	221
4.11.	Aim of the Present Work	221
4.12.	Docking Studies	222
4.13.	Synthetic Plan	229
4.14.	Results & Discussion: Plan of Work	229
4.15.	Chemical Synthesis of 3-Substituted-4-aryl-1-phenylamino-azetidin-2-ones (Xi–viii)	230
4.16.	Physical Properties and Spectral Discussion	233
4.16.1.	Physical Properties and Spectral Characteristics of 2-(Substitutedbenzylidene)-1-phenylhydrazines (Schiff's Bases) (IXi–iv)	233
4.16.2.	Physical Properties and Spectral Characteristics of 3-Substituted-4-aryl-1-phenylaminoazetidin-2-ones (Xi–viii)	237
4.17.	Biological Evaluation	242
4.18.	Experimental: Chemical Synthesis	245
4.18.1.	Synthesis of 2-(Substitutedbenzylidene)-1-phenylhydrazines (Schiff's Bases) (IXi–iv)	245
4.18.2.	Synthesis of 3-Substituted-4-aryl-1-phenylamino-azetidin-2-one (Xi–viii)	247
4.19.	Biological Screening	251
4.20.	References	253
5.	Some Targets for Antihyperlipidemic Drug Research: A review	259
5.1.	Introduction	259
5.2.	Current Drug Targets for Antihyperlipidemic Therapy	259
5.2.1.	Molecular Entities Involved in Absorption of Cholesterol [Inhibition of Cholesterol Absorption] (CAIs)	259
5.2.2.	Peroxisome Proliferation Activated Receptors (PPARs) [Agonists of PPARs]	261
5.2.3.	Acyl-CoA Cholesterol Acyl Transferase (ACAT) [Inhibitors of ACAT]	264
5.2.4.	Coenzyme Q10 (CoQ10) [Stimulators of CoQ10]	266

Contents

5.2.5.	ATP Citrate Lyase (ACL) [Inhibition/antagonist of ACL]	268
5.2.6.	Concentration of HDL Levels [Enhancers of HDL]	270
5.2.7.	Microsomal Triglyceride Transfer Protein (MTP) [Inhibitors of MTP]	272
5.2.8.	Cholesteryl Ester Transfer Protein (CETP) [Inhibition of CETP]	273
5.2.9.	C-reactive Protein (CRP) [Inhibition of CRP]	275
5.2.10.	Molecular Entities Involved in Lipid Oxidation [Inhibition of Lipid Oxidation; Antioxidants]	276
5.2.11.	Diacylglycerol O-acyltransferase (DGAT) [Inhibition of DGAT]	278
5.2.12.	Lanosterol 14 α -demethylase (LDM) [Inhibition of Human LDM (CYP51)]	280
5.2.13.	HMG-CoA Synthase [Inhibition of HMG CoA Synthase]	282
5.2.14.	Squalene Synthase (SqS) [Inhibition of SqS]	282
5.2.15.	Squalene Epoxidase (SQLE) [Inhibition of SQLE]	285
5.2.16.	2,3-Oxidosqualenelanosterol cyclase (Squalene 2,3-oxide-lanosterolcyclase) (OSC) [Inhibition of OSC]	287
5.2.17.	Farnesiod X receptor (FXR) [Agonists/antagonists of FXR]	289
5.2.18.	Sterol Regulatory Element Binding Proteins (SREBPs) [Inhibition of SREBPs]	291
5.2.19.	Plasma apo-E Related Peptides [Stimulation of Plasma apo-E]	293
5.2.20.	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) [Inhibition of PCSK9]	294
5.3.	References	297
6.	Docking Studies of Antihyperlipidemic Intermediates - the Thieno[2,3-<i>d</i>]pyrimidines; LM-1554 and LM-1576 with Some Molecular Targets Related to Hyperlipidemia - An Investigation into their Mechanism of Action, as well as, Development of a Novel MWI based One-pot Synthesis and Pharmacokinetic Study of LM-1576.	317
6.1.	Introduction	317
6.2.	Aim of the Present Work	318

Contents

6.3.	Results & Discussion	321
6.3.1.	Docking Studies	321
6.3.2.	Chemical Synthesis of 4-Chloro-2-(chloromethyl)-5-(4-chlorophenyl)thieno[2,3- <i>d</i>]pyrimidine (LM-1576)	339
6.3.3.	Physical Property and Spectral Discussion of 4-Chloro-2-(chloromethyl)-5-(4-chlorophenyl)thieno[2,3- <i>d</i>]pyrimidine (LM-1576)	341
6.3.4.	Biological Evaluation of LM-1554 and LM-1576	344
6.3.5.	Pharmacokinetic Study (Determination of LM-1576 in Rabbit Serum by HPLC)	346
6.4.	Experimental	351
6.4.1.	Docking Studies	351
6.4.2.	Chemical Synthesis: Synthetic Pathway of LM-1576	353
6.4.3.	Biological Screening of LM-1554 and LM-1576	355
6.4.4.	Pharmacokinetic Study (Determination of LM-1576 in Rabbit Serum by HPLC): Material and Methods	356
6.5.	References	360
	Summary and Conclusion	365
	Publications and Presentations	369